NY-AUGURY/GRUNDFOS
12.2.2020 14:02:14 CET | Business Wire | Press release
Grundfos , a world-leading pump and water technology company, and Augury , a fast-growing data analytics company and leading Digital Machine Health solution provider, are taking a major step toward digitizing water and utility infrastructure worldwide by signing a long-term strategic partnership. Together, they will develop smart diagnostics solutions and services for Grundfos’ customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005113/en/
The two companies have already been working together successfully over the past two years to test new products and service offerings across several markets and industries. Now, they are committing to the next step, offering a range of services and new business models enabled by connected equipment.
“By adding an AI-driven intelligence layer on top of existing assets, we can automatically collect mechanical and operational data, providing actionable machine health insights and diagnostics to our customers and service organisation,” says Tommy Due Høy, Group VP, Global Service & Solutions, Grundfos. He believes the partnership puts down a marker for future solutions.
“When we stand ten, fifteen years from now, this could end up being one of those defining moments where we took a real step forward,” he adds.
Augury works with the world’s largest manufacturers and industrial companies to transform their operations by providing real-time diagnostics regarding the health and performance of their machines. The combination of Augury’s AI-based solutions with Grundfos’ deep applications expertise has the potential to change water delivery and services as we know them.
“Water is at the core of how we live, work, and thrive - yet it often goes unnoticed,” says Saar Yoskovitz, Co-Founder and CEO of Augury. “Through this partnership Grundfos and Augury will work to make water a safer, more available and more useful resource for businesses, individuals and even nations worldwide.”
“We have spent the last eight years working with manufacturers and utilities to ensure that people around the world can always rely on the machines that matter and have seen first-hand the impact it brings. I am thrilled to be partnering with Grundfos to bring this impact to a wider market.”
“Our applications knowledge has consistently been the key differentiator for us to provide best-in-class pumping solutions to the world. As we prepare our portfolio for the future, it is key that we leverage this knowledge base to build more intelligence, IoT, remote monitoring and advanced diagnostics into our offerings to ensure differentiation, which is one of the highest priorities for Grundfos,” said Anupam Bhargava, Group Vice President, Industry at Grundfos.
About Grundfos
Grundfos develops water solutions for the world, setting the standard in terms of innovation, efficiency, reliability, and sustainability. Their solutions help partners and customers move water to where it is supposed to go, providing drinking water for the smallest villages and the highest skyscrapers, treating and removing wastewater and bringing heat and comfort to the world – or cool it down if needed. For the past 75 years, Grundfos’ mission has been to make the highest quality, most reliable equipment.
About Augury
Augury is building a world where people can always rely on the machines that matter. Augury supports its partners by enabling Digital Transformation through superior insights into the health and performance of the machines they use to make products, deliver services and improve lives. To learn more about Augury’s machine health solutions, visit www.augury.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
